Search clinical trials for: DNK333

Total 10 results

Novartis

Completed

Efficacy, Safety and Tolerability of DNK333 (25 and 100 mg Bid) in Women With Diarrhea-Predominant Irritable Bowel Syndrome (IBS-D) (CDNK333B2201)

Irritable Bowel Syndrome

United States
Novartis

Completed

Efficacy, Safety and Tolerability of DNK333 (25 mg Bid) in Women With Diarrhea-predominant Irritable Bowel Syndrome (IBS-D)

Irritable Bowel Syndrome With Diarrhea (IBS-D)

United States, Canada
Novartis

Completed

Efficacy of DNK333 in Patients With COPD and Cough

Chronic Obstructive Pulmonary Disease

United Kingdom, Netherlands
Novartis Pharmaceuticals

Completed

Safety and Efficacy of DNK333 in Atopic Dermatitis Patients

Pruritus in Patients With Atopic Dermatitis

Germany
Denali Therapeutics Inc.

Completed

A Study to Evaluate the Bioavailability and Safety of DNL343 in Healthy Volunteers

Healthy Volunteers

New Zealand
Denali Therapeutics Inc.

Recruiting

A Phase 1, Open-label Study of the Absorption, Metabolism, and Excretion of [14C]-DNL343 Following a Single Oral Dose in Healthy Male Participants

Healthy Volunteers

United States
Denali Therapeutics Inc.

Active, not recruiting

A Study to Determine the Safety, Pharmacokinetics, and Pharmacodynamics of DNL343 in Participants With Amyotrophic Lateral Sclerosis

Amyotrophic Lateral Sclerosis

United States, Netherlands
Denali Therapeutics Inc.

Completed

A Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of DNL343 in Healthy Volunteers

Healthy Volunteers

Netherlands
Merit E. Cudkowicz, MD
Denali Therapeutics Inc.

Enrolling by invitation

HEALEY ALS Platform Trial - Regimen G DNL343

Amyotrophic Lateral Sclerosis

United States
Merit E. Cudkowicz, MD
Massachusetts General Hospital

Recruiting

HEALEY ALS Platform Trial - Master Protocol

Amyotrophic Lateral Sclerosis

United States

3

Subscribe